<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472990</url>
  </required_header>
  <id_info>
    <org_study_id>MARCHE-DMD</org_study_id>
    <nct_id>NCT02472990</nct_id>
  </id_info>
  <brief_title>Biomechanical and Morphological Changes in Dystrophic Muscle</brief_title>
  <acronym>MARCHE-DMD</acronym>
  <official_title>Determining Biomechanical and Morphological Factors That Affect Children With Duchenne Muscular Dystrophy (DMD) Who Loss of the Ability to Walk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The loss of ability to walk in many children with DMD (Duchenne muscular Dystrophy) is a
      pejorative event. Biomechanical and morphological unknowledge about the loss of the walk
      ability in children with DMD is an obstacle in reeducative, pharmacological or surgical
      therapeutic targets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The loss of ability to walk in many children with DMD (Duchenne muscular Dystrophy) is a
      pejorative event. Biomechanical and morphological unknowledge about the loss of the walk
      ability in children with DMD is an obstacle in reeducative, pharmacological or surgical
      therapeutic targets. We suppose that there are muscular characteristics and predictive
      parameters of the loss of walk ability. The identification of these potential therapeutic
      targets would improve the surveillance and the clinical care but would also guide future
      clinical and fundamental trials too.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine biomechanical and morphological predictive factors of the loss of the walk ability of the children with DMD</measure>
    <time_frame>24 years</time_frame>
    <description>Determine the biomechanical factors (muscular atrophy, muscular strength, muscular shrinkage) and morphological (greasy infiltration, contractile portion, muscular geometry) predictive of the loss of the walk ability of the children with DMD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify the muscles wasting and their implication in the loss of strength and the walking ability</measure>
    <time_frame>24 years</time_frame>
    <description>Identify the muscles wasting and their implication in the loss of strength and walking. This will be made possible thanks to the predictive analysis and the evolutionary analysis of the MRI and strength before and after loss of walking ability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomechanical evolutionary data collected during the last 2 years of walking</measure>
    <time_frame>24 years</time_frame>
    <description>Biomechanical evolutionary data collected during the last 2 years of walking by the repetition of the analysis of the walking until the loss of the walking ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the relationship between the parameters of walking and the scrawny body morphological anomalies</measure>
    <time_frame>24 years</time_frame>
    <description>Establish the relationship between the parameters of walking and the scrawny body morphological anomalies (muscular Atrophy, greasy infiltration, contractile muscular portion, three-dimensional morphological parameters) by doing correlations analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Duchenne Dystrophy Muscular</condition>
  <arm_group>
    <arm_group_label>Duchenne muscular dystrophy children</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No drug and no placebo were used in this study. For 2h30 (time)
Measurement of leg strength using a dynamometer
Measurement of Motor Function
Walk test 6 minutes
Walk test 10 meters
Walk analysis: 3D recording of walking
Muscle MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy children</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No drug and no placebo were used in this study. For 2h30 (time)
Measurement of leg strength using a dynamometer
Measurement of Motor Function
Walk test 6 minutes
Walk test 10 meters
Walk analysis: 3D recording of walking
Muscle MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No drug and no placebo were used in this study</intervention_name>
    <description>measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI</description>
    <arm_group_label>Duchenne muscular dystrophy children</arm_group_label>
    <arm_group_label>Healthy children</arm_group_label>
    <other_name>Several parameters must be performed.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young man ou woman (5 to 17 years old) with Duchenne Muscular Dystrophy (confirmed by
             immunohistochimy on the muscular biopsy and/or mutation in the dystrophin confirmed by
             molecular biology)

          -  Time more than 7 secondes to test of 10 m and/or distance less than 330 m to walk test
             of 6 minutes. These values are recent markers to include children with a strong risk
             of loss of walking ability in 2 years.

          -  Parental inform sign consent and / or child inform consent

        Exclusion Criteria:

          -  Recent orthopaedic surgery of lower limbs (6 months)

          -  Other chronic disease associated, which have an impact on the walking

          -  Cognitive Deficiency or behavior disorders limiting the understanding of the study

          -  Children who can benefit ATU (translarna ® or other) during the study

          -  All MRI contradications : pacemaker or neurosensory stimulator or implantable
             defibrillator, neurosurgical valves, cochlear implant or ferromagnetic implants near
             nervous structures, brace, metallic prostheses, not cooperative or agitated patients,
             patient claustrophobic, pregnant woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvain BROCHARD, Dr</last_name>
    <phone>02 98 22 31 52</phone>
    <email>sylvain.brochard@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Brest</city>
        <state>Brittanny</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Brochard, Dr</last_name>
      <phone>02 98 22 31 52</phone>
      <email>sylvain.brochard@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain Brochard, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylviane Peudenier, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette Ropars, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Lille</city>
        <state>North</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marie CUISSET, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marie CUISSET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien DURIGNEUX, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Julien DURIGNEUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72650</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Colin, Dr</last_name>
      <phone>02 43 51 72 67</phone>
    </contact>
    <investigator>
      <last_name>Denis Colin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lyon</city>
        <zip>63677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Vuillerot, Dr</last_name>
      <phone>07 89 22 02 92</phone>
      <email>carole.vuillerot@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carole Vuillerot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie Fontaine, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann PEREON</last_name>
      <phone>02 40 08 36 17</phone>
    </contact>
    <investigator>
      <last_name>Yann PEREON</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël GROSS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karoline LODE-KOLZ, Dr</last_name>
      <phone>05 49 44 44 44</phone>
    </contact>
    <investigator>
      <last_name>Karoline LODE-KOLZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène Rauscent, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Hélène Rauscent, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle Lagrue, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle Lagrue, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHBA</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert Journel, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Hubert Journel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>morphological predictive factors</keyword>
  <keyword>Mechanical</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

